학술논문
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Document Type
Article
Author
Source
Subject
*SOMATIC mutation
*LUNG cancer
*
Language
ISSN
0007-0920
Abstract
A letter to the editor is presented in response to the article "Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts" by S. Li and colleagues published in a 2014 issue of the journal.